Alkem down 5% on charges of clinical study data manipulation

Shares of Alkem Lab fell by nearly 5 per cent today amid concerns that the European Medicines Agency (EMA) is reviewing some of its drugs following a red flag over clinical trial studies.
The scrip went down by 4.44 per cent to end at Rs 1,276.25 on BSE. During the day, it declined 7.45 per cent to Rs 1,236.
At NSE, shares of the company slipped 4.64 per cent to close at Rs 1,276.80.
The review of the drugs, which include anti-biotics cefuroxime and rulizole used to treat neurological disorder amyotrophic lateral sclerosis and sold both by Alkem and Slovenia's Krka, has been ordered after the German drug regulator raised concerns about trial study data.

Alkem conducted trials on the drugs at its Taloja facility in Maharashtra for Krka.
Meanwhile, Alkem on Saturday said it will submit "suitable clarifications" to EMA over the decision to review two drugs.
"We will be submitting suitable clarifications to EMA within the stipulated timeline to enable the Committee for Medicinal Products for Human Use (CHMP) to take a balanced risk-benefit view with respect to these two products," Alkem had said in a regulatory filing.